Share this article on:

Minimal-Access Left Ventricular Assist Device Implantation

Cheung, Anson MD*; Soon, Jia-Lin MD*; Bashir, Jamil MD*; Kaan, Annemarie RN; Ignaszewski, Andrew MD

Innovations:Technology and Techniques in Cardiothoracic and Vascular Surgery: July/August 2014 - Volume 9 - Issue 4 - p 281–285
doi: 10.1097/IMI.0000000000000086
Original Articles

Objective The left ventricular assist device (LVAD) is typically implanted through a full sternotomy on cardiopulmonary bypass (CPB). Minimally invasive surgery (MIS) modifications include multiple smaller incisions, using “virgin” territory, and minimized CPB time.

Methods Forty-two LVAD implantations were retrospectively reviewed. Twenty-five minimally invasive implantations (MIS, 20 HeartMate II and 5 HeartWare) were compared with 17 sternotomy implantations (12 HeartMate II and 5 HeartWare). The choice of MIS incisions was device dependent: (1) three separate incisions for the HeartMate II or (2) two incisions for the HeartWare device. Four HeartWare LVADs were implanted off-pump (three using the MIS approach).

Results The median patient age was 52 years (range, 18–69 years). Overall survival was 81% at a mean (SD) follow-up of 495 (375) days. Thirty-day mortality was 9.5% (one MIS and three sternotomy patients). Five patients (11.9%) died while on LVAD, 18 (42.9%) underwent transplantation, 6 (14.3%) underwent weaning and explantation, and 13 (31.0%) remained on support. Preoperative ventilatory and circulatory supports were more common in the sternotomy group. The MIS patients had shorter CPB time [51.4 (34.9) vs 83.6 (40.4) minutes, P = 0.014] and showed a trend toward lower red blood cell and platelet transfusion requirement. The durations of hospitalization, inotropic support, intensive care unit stay, and LVAD support were not significantly different.

Conclusions Minimally invasive surgery LVAD implantation is feasible. The shorter CPB duration and off-pump approach may be advantageous. Avoiding sternotomy may also reduce adhesions encountered during subsequent cardiac transplantation.

From the Division of *Cardiovascular Surgery, and †Department of Cardiology, St Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Accepted for publication January 8, 2014.

Disclosures: Anson Cheung, MD, is a consultant for HeartWare International, Inc, Framingham, MA USA. Jia-Lin Soon, MD; Jamil Bashir, MD; Annemarie Kaan, RN; and Andrew Ignaszewski, MD, declare no conflicts of interest.

Address correspondence and reprint requests to Anson Cheung, MD, Department of Cardiovascular Surgery, St Paul’s Hospital, Room 484-1081 Burrard St, Vancouver, BC V6Z 1Y6 Canada. E-mail: acheung@providencehealth.bc.ca.

©2014 by the International Society for Minimally Invasive Cardiothoracic Surgery